Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents

Leuk Lymphoma. 2022 Dec;63(13):3245-3248. doi: 10.1080/10428194.2022.2113530. Epub 2022 Sep 15.

Authors

Carl Zainaldin¹, Sankalp Arora¹, Srilakshmi Bathini², Udita Gupta¹, Vishruti Pandya³, Sejong Bae³, Sarah Worth⁴, Kimo Bachiashvili², Ravi Bhatia², Kelly Godby², Omer Jamy², Sravanti Rangaraju², Barry Diamond⁴, Josh D Oliver⁴, Donna Salzman², Antonio Di Stasi², Pankit Vachhani²

Affiliations

¹ Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
² Divison of Hematology/Oncology, Dept of Medicine, University of at Birmingham, Birmingham, AL, USA.
³ Divison of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
⁴ Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USA.

PMID: 36107006
DOI: 10.1080/10428194.2022.2113530

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Humans
Leukemia, Myeloid, Acute*
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides